Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07022470 · ClinicalTrials.gov registry record · Phase 2
Phase II Trial Comparison of 3 vs 4 Fractions (BRACHY-FIT).
A Phase 2 study of Cervical Cancers, sponsored by Stanford University.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 41
- Enrollment target
- 1
- Study location
NCT07022470: Recruiting Phase 2 study of Cervical Cancers, sponsored by Stanford University.
NCT07022470 is a Phase 2 study of Cervical Cancers that is actively recruiting participants, run by Stanford University. The registered enrollment target is 41 participants, below the 356-participant average among 3 other Cervical Cancers trials with a reported enrollment target (88% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07022470, a Phase 2 study of Cervical Cancers, is actively recruiting participants, sponsored by Stanford University.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 41 participants
- Enrollment target
- 1
- Study location
Study Summary
This is a prospective non-randomized clinical trial to evaluate the feasibility of 3 fraction versus a standard 4 fraction high dose rate brachytherapy regimen in patients with locally advanced cervical cancer.
Primary Outcome
Proportion of patients that underwent a 3 fraction brachytherapy regimen.
Conditions Studied
Interventions
- RADIATION 3-Fraction HDR Brachytherapy
- RADIATION 4-Fraction HDR Brachytherapy
Study Locations (1)
California
- Stanford University - Palo Alto
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 41 participants |
| Start Date | 2025-06-03 |
| Est. Completion | 2028-06 |
| Phase | Phase 2 |
What NCT07022470 shows while recruiting
NCT07022470 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 41 participants, a relatively small participant target, below the 356-participant average among 3 other Cervical Cancers trials with a reported enrollment target (88% lower).
The record links to 1 condition, with Cervical Cancers appearing as the primary indexed condition, and to 2 interventions - of which 3-Fraction HDR Brachytherapy is the first listed.
NCT07022470 reports a single indexed study location in California.
Frequently Asked Questions
What is clinical trial NCT07022470 about?
NCT07022470 is a clinical study titled "Phase II Trial Comparison of 3 vs 4 Fractions (BRACHY-FIT).". This is a prospective non-randomized clinical trial to evaluate the feasibility of 3 fraction versus a standard 4 fraction high dose rate brachytherapy regimen in patients with locally advanced cervical cancer.
What is the current status of trial NCT07022470?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 41 participants. The study started on 2025-06-03. Estimated completion is 2028-06.
What conditions does trial NCT07022470 study?
This clinical trial studies the following conditions: Cervical Cancers.
What interventions are being tested in trial NCT07022470?
The interventions under investigation include: 3-Fraction HDR Brachytherapy (RADIATION), 4-Fraction HDR Brachytherapy (RADIATION).
Who is sponsoring clinical trial NCT07022470?
This trial is sponsored by Stanford University, which has 1,744 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07022470 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Cervical Cancers
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03449238 · 41 participants · Phase 1
Pembrolizumab And Stereotactic Radiosurgery (Srs) Of Selected Brain Metastases In Breast Cancer Patients
- NCT03900793 · 41 participants · Phase 1
Losartan + Sunitinib in Treatment of Osteosarcoma
- NCT04082520 · 41 participants · Phase 2
Lutathera for the Treatment of Inoperable, Progressive Meningioma After External Beam Radiation Therapy
- NCT04220190 · 41 participants · Phase 2
RAPA-501 Therapy for ALS
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI